Rapafusyn

R&D

Partner Content

Baltimore, MD – February 5, 2024 – Rapafusyn proudly announces the distinguished recognition of Dr.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.